Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03464097 · ClinicalTrials.gov registry record · Phase 3
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
A Phase 3 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 3
- Development phase
- 550
- Enrollment target
NCT03464097 is a Phase 3 study that was terminated before completion, run by Celgene. The registered enrollment target is 550 participants.
The verdict
NCT03464097, a Phase 3 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 550 participants
- Enrollment target
Study Summary
This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.
Interventions
- OTHER Placebo
- DRUG Ozanimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2018-06-27 |
| Est. Completion | 2024-10-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03464097
The ClinicalTrials.gov registry entry for NCT03464097 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03464097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03464097 about?
NCT03464097 is a clinical study titled "A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease". This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.
What is the current status of trial NCT03464097?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 550 participants. The study started on 2018-06-27. Estimated completion is 2024-10-03.
What interventions are being tested in trial NCT03464097?
The interventions under investigation include: Placebo (OTHER), Ozanimod (DRUG).
Who is sponsoring clinical trial NCT03464097?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.